TABLE 1.
Baseline clinical characteristics of the study population according to IL6 levels.
| Study population (n = 57) | Low IL6 (n = 38) |
High IL6 (n = 19) |
P-value | |
| Age; median (IQR) | 63 (53–81) | 60 (49–81) | 72 (59–81) | 0.21 |
| Male sex; n (%) | 35 (61.4) | 19 (50) | 16 (84.2) | 0.02 |
| Race/ethnicity; n (%) -Caucasian -Latin-American -Asian |
39 (68.4) 16 (28.1) 2 (3.5) |
22 (57.9) 15 (39.5) 1 (2.6) |
17 (89.4) 1 (5.3) 1 (5.3) |
0.009 *0.01 |
| Comorbidities; n (%) | 43 (75.4) | 30 (79) | 13 (68.4) | 0.5 |
| Age-adjusted Charlson’s Comorbidity Index; median (IQR) | 3 (1–5) | 2.5 (1–5) | 4 (1–5) | 0.37 |
| Days from symptom onset to first sample; median (IQR) | 8 (4–10) | 8 (4–12) | 6 (3–8) | 0.12 |
| Persistent viremia; n (%) | 16 (28.1) | 5 (13.2) | 11 (57.9) | 0.001 |
| Clinical progression^; n (%) | 12 (21.1) | 3 (7.9) | 9 (47.4) | 0.001 |
| Intensive Care Unit; n (%) | 8 (14) | 3 (7.9) | 5 (26.3) | 0.1 |
| In-hospital mortality; n (%) | 5 (8.8) | 0 | 5 (26.3) | 0.003 |
*Significant differences were only found between Caucasians and Latin-Americans. ^Clinical progression was defined as a worsening of at least one point on the WHO COVID Ordinal Outcomes Scale (33) during a 14-day follow-up after admission.